Leukemias pp 199-204 | Cite as

CD48 Monoclonal Antibody K31 for Bone Marrow Transplantation: Functional Characteristics

  • P. Dreger
  • B. Mueller
  • N. Schmitz
  • H. Löffler
  • W. Müller-Ruchholtz
Conference paper

Abstract

In clinical bone marrow (BM) transplantation, graft-versus-host reaction can be effectively prevented by depleting the graft of T cells. However, transplantation of T-depleted grafts is complicated by a high incidence of graft rejection due to residual immunological reactivity of the host and the immunogenicity of the graft [1]. Recent reports suggest that the immunogenicity of an organ graft is largely due to BM-derived “accessory cells” (AC) that are distributed in the organ, whereas the cells that are essential for the graft’s function do not play nearly as important a role in immunogenicity [2]. In this context, we have been able to demonstrate that the CD48 monoclonal antibody (MoAb) K31 binds to almost all human lymphoid cells, and, in addition, to macrophage cells with high accessory capacity, such as monocytes, dendritic cells, and veiled accessory cells. On the other hand, no other hemopoietic or nonhemopietic cells, including progenitors, are labeled by K31 [3,4]. In the present paper, we report that K31 is cytotoxic with rabbit complement (C) but not with human C. Because it completely eliminates BM AC, K31 + C strongly reduces the allostimulatory capacity and thus the immunogenicity of BM mononuclear cells (BMNC). In contrast, the CDw52 MoAb CAMPATH-1 or T cell-specific MoAbs do not affect BM immunogenicity.

Keywords

Chromium Leukemia Thymidine Allo Glyco 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sondei PM, Hank JA, Trigg ME, Kohler PC, Finlay JL, Blank J, Meisner L, Borcherding W, Hong R, Steeves R, Billing R, Flynn B, Bozdech MJ (1986) Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: autologous marrow recovery with specific immune sensitization to donor antigens. Exp Hematol 14: 278Google Scholar
  2. 2.
    Lechler RI, Batchelor JR (1982) Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 155: 31PubMedCrossRefGoogle Scholar
  3. 3.
    Dreger P, Müller-Ruchholtz W (1990) Evidence that reduction of immunogenicity of T-depleted bone marrow depends on additional depletion of accessory cells. Implications for prevention of graft rejection. Transplantation 49: 622PubMedCrossRefGoogle Scholar
  4. 4.
    Dreger P, Viehmann K, Löffler H, Müller-Ruchholtz W (1990) A CD48 monoclonal antibody for reduction of graft immunogenicity. Transplant Proc 22: 1930PubMedGoogle Scholar
  5. 5.
    Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H (1983) Removal of T cells from bone marrow for transplantation: a monoclonal anti-lymphocyte antibody that fixes human complement. Blood 62: 873PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • P. Dreger
    • 1
  • B. Mueller
  • N. Schmitz
  • H. Löffler
  • W. Müller-Ruchholtz
  1. 1.Departments of Internal Medicine II and ImmunologyUniversity of KielKielGermany

Personalised recommendations